Pharmacogenomic assessment of treatment options in gestational diabetes.
Gene expression profiles offer a multidimensional view of metabolic diseases, typically characterized by a single parameter, and can provide a basis for choosing between therapies yielding a common clinical end point. We applied such an approach in gestational diabetes mellitus (GDM). Gene expression was examined in four maternal tissues and placentas from normal patients and euglycemic GDM patients, undergoing elective Cesarean sections at term, treated either by diet or diet plus insulin. Deviations from normal were 11-fold greater for the patients treated by diet, alone, than for patients treated by diet plus insulin. Assuming the achievement of a "normal" gene expression profile, in addition to euglycemia, is a desirable outcome of treatment, insulin treatment appears to have a beneficial effect in the treatment of GDM. Subsequently, we utilized the expression data to identify serum biomarkers that provide ways to monitor the benefits of insulin treatment in GDM.
Ort
T
T
CuraGen Corporation, Branford, CT, USA.
Voss
M
M
Lichtmacher
A
A
Saidel
M
M
DeFrancesco
M
M
Greenberg
P
P
Hunt
B
B
Eisen
A
A
D000273:Adipose Tissue / Q000378:metabolism; D002585:Cesarean Section; D018932:Chemokine CCL2 / Q000096:biosynthesis / Q000235:genetics; D003131:Combined Modality Therapy; D016640:Diabetes, Gestational / Q000178:diet therapy / Q000235:genetics* / Q000628:therapy*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D010597:Pharmacogenetics; D011247:Pregnancy
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D007328:Insulin